A phase II study of prostatic acid phosphatase-pulsed dendritic cells (Provenge) [sipuleucel T] in combination with bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy

Trial Profile

A phase II study of prostatic acid phosphatase-pulsed dendritic cells (Provenge) [sipuleucel T] in combination with bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2013

At a glance

  • Drugs Sipuleucel-T (Primary) ; Bevacizumab
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Aug 2007 Status changed from in progress to completed.
    • 30 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top